Skip to content
Open access · CC-BY via OpenAlex

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats

Ekaterina A. Lesovaya, Кирсанов Кирилл Игоревич, Elena E. Antoshina, Lubov S. Trukhanova, Tatiana G. Gorkova, Elena V. Shipaeva, Рамиз Меджидович Салимов, Gennady A. Belitsky, Mikhail V. Blagosklonny, Якубовская Марианна Геннадиевна, Olga B. Chernova

Oncotarget · 2015 · ▲ 33 citations

Abstract

// Ekaterina A. Lesovaya 1,* , Kirill I. Kirsanov 1,* , Elena E. Antoshina 1 , Lubov S. Trukhanova 1 , Tatiana G. Gorkova 1 , Elena V. Shipaeva 2 , Ramiz M. Salimov 2 , Gennady A. Belitsky 1 , Mikhail V. Blagosklonny 3 , Marianna G. Yakubovskaya 1,** and Olga B. Chernova 4,** 1 Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia 2 Tartis-Aging LLC, Moscow, Russia 3 Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA 4 Everon Biosciences, Inc., Buffalo, NY, USA * The first two authors made equal contributions to the study ** The last two authors made equal contributions to the study Correspondence to: Marianna Yakubovskaya, email: // Olga B. Chernova, email: // Keywords : gerotarget, aging, benign prostatic hyperplasia, mTOR(definition), rapamycin(definition) Received : December 8, 2014 Accepted : April 15, 2015 Published : April 26, 2015 Abstract Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.18632/oncotarget.3929
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Lesovaya, E.A., Игоревич, �.�., Antoshina, E.E., Trukhanova, L.S., Gorkova, T.G., Shipaeva, E.V., Салимов, �.�., Belitsky, G.A., Blagosklonny, M.V., Геннадиевна, �.�., &amp; Chernova, O.B. (2015). Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats. <em>Oncotarget</em>. https://doi.org/10.18632/oncotarget.3929
Vancouver
Lesovaya EA, Игоревич ��, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, et al. Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats. Oncotarget. 2015. doi:10.18632/oncotarget.3929.
BibTeX
@article{ekaterina2015Rapata, title = {Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats}, author = {Ekaterina A. Lesovaya and Кирсанов Кирилл Игоревич and Elena E. Antoshina and Lubov S. Trukhanova and Tatiana G. Gorkova and Elena V. Shipaeva and Рамиз Меджидович Салимов and Gennady A. Belitsky and Mikhail V. Blagosklonny and Якубовская Марианна Геннадиевна and Olga B. Chernova}, journal = {Oncotarget}, year = {2015}, doi = {10.18632/oncotarget.3929}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings